Results 61 to 70 of about 9,498 (160)

Real‐World Impact of a Simplified ‘Test and Treat’ Strategy for In‐Hospital HCV Micro‐Elimination

Journal of Viral Hepatitis, Volume 33, Issue 3, March 2026.
ABSTRACT Hepatitis C virus (HCV) micro‐elimination faces challenges from fragmented care pathways, particularly in high‐prevalence regions with complex genotypes and socioeconomic barriers. This study evaluated a simplified ‘Test and Treat’ (TNT) strategy to enhance in‐hospital HCV micro‐elimination by reducing delays and improving linkage to care ...
Chunfang You, Yuting Diao, Juan Tang, Jing Tang, Wei Deng, Chunqi Zheng, Dongxia Liao, Dan Song, Jie Wang, Yangyang Pu   +9 more
wiley   +1 more source

Unveiling the Crucial Nexus: Mitochondrial Quality Control as a Central Driver in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis

Cell Proliferation, Volume 59, Issue 2, February 2026.
Mitochondrial quality control (MQC) impairment plays a central role in driving the pathogenesis of metabolism‐associated steatotic liver disease (MASLD). Specifically, this is manifested as reduced mitophagy; increased mitochondrial fission and decreased fusion; and impaired mitochondrial biogenesis.
Wenkai Fu, Junqi Wang, Nan Lu, Zhijiang Guo, Sang‐Bing Ong, Yong Gao, Hao Zhou, Xing Chang, Miao Meng   +8 more
wiley   +1 more source

Changing the face of hepatitis C management – the design and development of sofosbuvir

Drug Design, Development and Therapy, 2015
Bennett C Noell,* Siddesh V Besur,* Andrew S deLemos Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, NC, USA *These authors contributed equally to this work Abstract: The availability of
Noell BC, Besur SV, deLemos AS
doaj  

Successful Treatment Using Simeprevir, Sofosbuvir and Rituximab of a Severe Form of Hepatitis C Virus-related Mixed Cryoglobulinemia with Cardiac Involvement

European Journal of Case Reports in Internal Medicine, 2015
Numerous extrahepatic manifestations have been reported in hepatitis C virus (HCV) infection, particularly mixed cryoglobulinemia (MC). MC generally responds to clearance of HCV under pegylated-interferon plus ribavirin treatment.
Rafael Mahieu, Christian Lavigne, Geoffrey Urbanski, Isabelle Fouchard Hubert, Alexandra Ducancelle, Françoise Lunel-Fabiani   +5 more
doaj   +1 more source

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C

Journal of Rawalpindi Medical College, 2017
Background:To determine the effectiveness of sofosbuvir plus ribavirin in terms of frequency of negative qualitative PCR at 2nd week of treatment in chronic hepatitis C patients with genotype 3.
Aqsa Naseer
doaj  

Sofosbuvir [PDF]

Reactions Weekly, 2020
  +5 more sources

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region [PDF]

International Journal of Advanced Humanities Research
The liver is the largest organ in the body, located below the diaphragm and protected by the lower ribs of the rib cage (Johns Hopkins Medicine, 2022).
Fahad Alghamdi, Rashed Mohammed
doaj   +1 more source

EFFICACY AND BENEFICIAL EFFECTS OF SOFOSBUVIR WITH DACLATASVIR ON LIVER FUNCTIONS OF EARLIER TREATMENT FAILURE PATIENTS INFECTED WITH GENOTYPE 3 OF HEPATITIS C VIRUS

Pakistan Armed Forces Medical Journal, 2020
Objective: To evaluate the efficacy of sofosbuvir with daclatasvir and its promising effects on liver functions especially in respect to earlier treatment failure patients to frame an appropriate regimen for them.
Sumetha Yaseen, Kulsoom Farhat, Mahwish Gul, Syeda Urooj Zaidi, Maryam Saqib, Ayman Zafar   +5 more
doaj  

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

ClinicoEconomics and Outcomes Research, 2015
David R Walker, Timothy R Juday, Shivaji R Manthena, Yonghua Jing, Vipan Sood Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA Background: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat ...
Walker DR, Juday TR, Manthena SR, Jing Y, Sood V   +4 more
doaj  

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj